Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

ervations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine whether any can be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements si
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Participant Eyes with Wet AMD ... to Electronic Case Report Forms (eCRFs), ... clinical data solutions on demand company, today expanded its,international ... device company specializing in the early detection of,AMD, has ...
... Dec. 13 Anesiva,Inc. (Nasdaq: ANSV ) ... offering,of 11,111,111 shares of its common stock at ... closing bid price on December 12, 2007, for,approximately ... and commissions (approximately $50 million if the underwriters,over-allotment ...
... existing current 2008 convertible notes, and extended the maturity to 2011 on ... ... Dec. 13 Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: ... Convertible Senior,Notes (the "New Notes") due 2011 and 5,459,574 shares of its ...
Cached Biology Technology:Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 2Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 3Anesiva Raises $45 Million in Common Stock Offering 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3
(Date:8/21/2014)... University (ANU) team has successfully replicated one of the ... systems powered by sunlight which could manufacture hydrogen as ... sunlight. It is an exciting prospect to use them ... said Dr Kastoori Hingorani, from the ARC Centre of ... of Biology. , Hydrogen offers potential as a zero-carbon ...
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... research finds life can persist in a cold, dark ... a team that examined waters and sediments from a ... found the extreme environment supports microbial ecosystems. , ... her colleagues has implications for life in other extreme ... The findings are published in the current edition of ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... study by researchers at the Salk Institute for Biological ... its name as "guardian of the genome", not only ... but also controls somatic cell reprogramming. Although scientists ... as skin cells into so-called induced pluripotent stem cells ...
... A chemical found in blueberry leaves has shown a strong ... opening up a new avenue for treating chronic HCV infections, ... to cirrhosis and liver cancer. Among the areas ... of southern Japan, a trend that led Hiroaki Kataoka and ...
... numbers of novel marine microbes could lead to more ... conditions such as epilepsy, diabetes, flu and other viruses, ... such as agrochemicals. Researchers at Heriot-Watt University and ... company Ingenza Ltd are searching for new enzymes for ...
Cached Biology News:Tumor suppressor pulls double shift as reprogramming watchdog 2Tumor suppressor pulls double shift as reprogramming watchdog 3Marine microbes creating green waves in industry 2Marine microbes creating green waves in industry 3
Chicken anti-EEA1...
... Buffers are membrane-filtered isotonic and enzyme-free ... and cell-conditioning agents in either Ca2+- ... or Ca2+- and Mg2+-free phosphate-buffered ... cells from support substrates and each ...
Request Info...
Request Info...
Biology Products: